Sixty Years of Lung Cancer Screening: From Sputum Cytology to Low-Dose CT and the Emerging Precision Era.
To trace the evolution of lung cancer screening from early radiographic and sputum cytology trials through the landmark randomized trials that established low-dose computed tomography (LDCT) as a guideline-endorsed intervention, and to examine emerging technologies poised to transform the field. A narrative synthesis of primary trial literature, guideline documents, and emerging research conducted March-May 2026.
To trace the evolution of lung cancer screening from early radiographic and sputum cytology trials through the landmark randomized trials that established low-dose computed tomography (LDCT) as a guideline-endorsed intervention, and to examine emerging technologies poised to transform the field. A narrative synthesis of primary trial literature, guideline documents, and emerging research conducted March-May 2026.
What the study was
- Study design
- Review
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Acad Radiol
Why it surfaced
Matched watchlist topic 'Early cancer detection (liquid biopsy, ctDNA, cfDNA)'. Study design: Review. Score: 8/10 (N:2, R:3, D:1, P:2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.